Colon cancer is not identified as a safety concern in the medicine's Summary of Product Characteristics
In Phase 2 clinical trials, retatrutide was administered as a once-weekly subcutaneous injection using a structured dose-escalation schedule to improve gastrointestinal tolerability
If you are new to self-injection, the peptide injections guide provides step-by-step instruction on proper subcutaneous injection technique, and the article on where to inject GLP-1 identifies the preferred injection sites
The nasal mucosa is highly vascularized, allowing absorption directly into circulation, and some evidence suggests nasal administration may provide more direct central nervous system access via the olfactory pathway
KLOW occupies a middle position
Additionally, emerging evidence suggests that GLP-1 receptor agonists like semaglutide may offer direct renal protection by reducing albuminuria and stabilizing kidney function, although more research is needed to fully understand these effects